Genetic testing by cancer site: Breast

Cancer Journal (United States)

Volumn 18, Issue 4, 2012, Pages 310-319

  Shannon, Kristen Mahoney ^a   Chittenden, Anu ^b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

BRCA1; BRCA2; CDH1; Cowden syndrome: hereditary breast and ovarian cancer (HBOC) syndrome; Li Fraumeni syndrome (LFS); Peutz Jeghers syndrome (PJS); PTEN; STK11; TP53

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RALOXIFENE; TAMOXIFEN;

BILE DUCT CANCER; BREAST CANCER; BREAST EXAMINATION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; COLORECTAL CANCER; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; HEPATOBLASTOMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LYMPHOMA; MASTECTOMY; MELANOMA; MUTATIONAL ANALYSIS; NASOPHARYNX CANCER; ORAL CONTRACEPTION; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SEQUENCE ANALYSIS; STOMACH CANCER; TESTIS CANCER; URETER CANCER;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; NEOPLASTIC SYNDROMES, HEREDITARY; RISK ASSESSMENT;

EID: 84864620195     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318260946f     Document Type: Review

References (114)

1. Howlander N, NooneAM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
2. Bennett RL, et al. Standardized human pedigree nomenclature: Update and assessment of the recommendations of the National Society of Genetic Counselors. J Genet Couns. 2008;17:424-433.
3. Bennett RL, et al. Recommendations for standardized human pedigree nomenclature. Pedigree Standardization Task Force of the National Society of Genetic Counselors. Am J Hum Genet. 1995;56:745-752.
4. Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. J Chronic Dis. 1985;38:289-293.
5. Theis B, et al. Accuracy of family cancer history in breast cancer patients. Eur J Cancer Prev. 1994;3:321-327.
6. Reid GT, et al. Family history questionnaires designed for clinical use: A systematic review. Public Health Genomics. 2009;12:73-83.
7. Jefferies S, Goldgar D, Eeles R. The accuracy of cancer diagnoses as reported in families with head and neck cancer: A case-control study. Clin Oncol (R Coll Radiol). 2008;20:309-314.
8. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA. 2004;292:1480-1489.
9. Chang ET, et al. Reliability of self-reported family history of cancer in a large case-control study of lymphoma. J Natl Cancer Inst. 2006;98:61-68.
10. Ziogas A, et al. Clinically relevant changes in family history of cancer over time. JAMA. 306:172-178.
11. Walsh T, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295: 1379-1388.
12. Ford D, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
13. Frank TS, et al. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16:2417-2425.
14. Miki Y, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66-71.
15. Wooster R, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-792.
16. Struewing JP, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
17. Kauff ND, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002;39:611-614.
18. Thorlacius S, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996;13:117-119.
19. Unger MA, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000;67:841-850.
20. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol. 2000;18:287-295.
21. Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different? J Clin Oncol. 1999;17:3653-3663.
22. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: A critical review. J Clin Oncol. 2008;26:2568-2581.
23. Boyd J, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-2265.
24. Lakhani SR, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10:2473-2481.
25. Levine DA, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21:4222-4227.
26. Cass I, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187-2195.
27. Arun B, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: A single-institution experience. J Clin Oncol. 29:3739-3746.
28. Berry DA, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701-2712.
29. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111-1130.
30. Couch FJ, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409-1415.
31. Shattuck-Eidens D, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997;278:1242-1250.
32. Kang HH, et al. Evaluation of models to predict BRCA germline mutations. Br J Cancer. 2006;95:914-920.
33. Barcenas CH, et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006;24:354-360.
34. James PA, et al. Optimal selection of individuals for BRCA mutation testing: A comparison of available methods. J Clin Oncol. 2006;24: 707-715.
35. Saslow D, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.
36. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-646.
37. Ozcelik H, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet. 1997;16:17-18.
38. Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
39. Risch HA, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.
40. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310-1316.
41. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358-1365.
42. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68:410-419.
43. van Asperen CJ, et al. Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. J Med Genet. 2005;42:711-719.
44. Hartmann LC, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001; 93:1633-1637.
45. Rebbeck TR, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol. 2004;22:1055-1062.
46. Meijers-Heijboer H, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159-164.
47. Robson M, et al. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series. Cancer. 2005;103:44-51.
48. Narod SA, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356:1876-1881.
49. Gronwald J, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer. 2006;118:2281-2284.
50. Kauff ND, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615.
51. Rebbeck TR, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
52. Piver MS, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 1993;71: 2751-2755.
53. Modan B, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:235-240.
54. Narod SA, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998;339:424-428.
55. Narod SA, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002;94: 1773-1779.
56. NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancer; V.1.2011. 2011 Available at http://www.nccn.org. Accessed April 23, 2012.
57. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol. 2004;22:735-742.
58. DiCastro M, et al. Genetic counseling in hereditary breast/ovarian cancer in Israel: Psychosocial impact and retention of genetic information. Am J Med Genet. 2002;111:147-151.
59. Lodder LN, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: Emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat. 2002;73:97-112.
60. Crotser CB, Boehmke M. Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: State of the science. J Cancer Surviv. 2009;3:21-42.
61. Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: A meta-analytic review. Health Psychol. 2009;28:510-518.
62. Reichelt JG, et al. Psychological and cancer-specific distress at 18 months post-testing in women with demonstrated BRCA1 mutations for hereditary breast/ovarian cancer. Fam Cancer. 2008;7:245-254.
63. Lodder L, et al. Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet. 2001;98:15-24.
64. Power TE, et al. Distress and psychosocial needs of a heterogeneous high risk familial cancer population. J Genet Couns. 20:249-269.
65. O'Neill SC, et al. Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology 2009;18: 1088-1096.
66. Di Prospero LS, et al. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: Findings from a focus group and a needs-assessment survey. CMAJ. 2001;164:1005-1009.
67. Ertmanski S, et al. Identification of patients at high risk of psychological distress after BRCA1 genetic testing. Genet Test Mol Biomarkers. 2009;13:325-330.
68. Roussi P, et al. Enhanced counselling for women undergoing BRCA1/2 testing: Impact on knowledge and psychological distress-results from a randomised clinical trial. Psychol Health. 2010;25:401-415.
69. Shochat T, Dagan E. Sleep disturbances in asymptomatic BRCA1/2 mutation carriers: women at high risk for breast-ovarian cancer. J Sleep Res. 19:333-340.
70. Werner-Lin A. Formal and informal support needs of young women with BRCA mutations. J Psychosoc Oncol. 2008;26:111-133.
71. Werner-Lin A. Beating the biological clock: The compressed family life cycle of young women with BRCA gene alterations. Soc Work Health Care. 2008;47:416-437.
72. Metcalfe KA, et al. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. J Med Genet. 2000;37:866-874.
73. McKinnon W, et al. Results of an intervention for individuals and families with BRCA mutations: A model for providing medical updates and psychosocial support following genetic testing. J Genet Couns. 2007; 16:433-456.
74. Lodder L, et al. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: An exploration of attitudes and psychological functioning during genetic testing. Eur J Hum Genet. 2001;9:492-500.
75. Sidransky D, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992;52:2984-2986.
76. Malkin D, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250: 1233-1238.
77. Birch JM, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994; 54:1298-1304.
78. Srivastava S, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348: 747-749.
79. Varley JM, et al. Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res. 1997;57:3245-3252.
80. Li FP, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-5362.
81. Gonzalez KD, et al. Beyond Li Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27:1250-1256.
82. Nichols KE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001;10:83-87.
83. Hwang SJ, et al. Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am J Hum Genet. 2003;72: 975-983.
84. Kleihues P, et al. Tumors associated with p53 germline mutations: A synopsis of 91 families. Am J Pathol. 1997;150:1-13.
85. Olivier M, et al. Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63:6643-6650.
86. Birch JM, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20:4621-4628.
87. Strong LC, Williams WR, Tainsky MA. The Li-Fraumeni syndrome: From clinical epidemiology to molecular genetics. Am J Epidemiol. 1992;135:190-199.
88. Chompret A, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000;82:1932-1937.
89. Chompret A, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001;38:43-47.
90. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndromeVa molecular and clinical review. Br J Cancer. 1997;76:1-14.
91. Frebourg T, et al. Germ-line p53 mutations in 15 families with Li- Fraumeni syndrome. Am J Hum Genet. 1995;56:608-615.
92. Brugieres L, et al. Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer. Cancer Res. 1993;53:452-455.
93. Le Bihan C, et al. ARCAD: A method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet Epidemiol. 1995;12:13-25.
94. Wu CC, et al. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res. 2006;66:8287-8292.
95. Hisada M, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90:606-611.
96. Dorval M, et al. Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: Findings from p53 and BRCA1 testing programs. J Clin Oncol. 2000;18:2135-2142.
97. Peterson SK, et al. Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. Psychooncology 2008;17:783-789.
98. Oppenheim D, et al. The psychological burden inflicted by multiple cancers in Li-Fraumeni families: Five case studies. J Genet Couns. 2001;10:169-183.
99. Nelen MR, et al. Novel PTEN mutations in patients with Cowden disease: Absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7:267-273.
100. PTEN Hamartoma Tumor Syndrome (PHTS). 2011. Available at http//www.ncbi.nlm.nih.gov/books/NBK1488/. Accessed April 23, 2012.
101. Zhou XP, et al. Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan- Riley-Ruvalcaba syndromes. Am J Hum Genet. 2001;69:704-711.
102. Ni Y, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet. 2008;83:261-268.
103. Eng C. Will the real Cowden syndrome please stand up: Revised diagnostic criteria. J Med Genet. 2000;37:828-830.
104. Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400-407.
105. Pilarski R. Cowden syndrome: A critical reviewof the clinical literature. J Genet Couns. 2009;18:13-27.
106. Conti S, et al. Phosphatase and tensin homolog (PTEN) gene mutations and autism: Literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy. J Child Neurol. 2012;27: 392-397.
107. Smith JR, et al. Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. J Clin Endocrinol Metab. 2011;96:34-37.
108. Zbuk KM, Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol. 2007;4:492-502.
109. Kutscher AH, et al. Incidence of Peutz-Jeghers syndrome. Am J Dig Dis. 1960;5:576-577.
110. Beggs AD, et al. Peutz-Jeghers syndrome: A systematic review and recommendations for management. Gut. 2010;59:975-986.
111. Lim W, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004;126:1788-1794.
112. Hearle N, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209-3215.
113. Fitzgerald RC, et al. Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436-444.
114. Kluijt I, et al. Familial gastric cancer: Guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer. 2012 Mar 3. [Epub ahead of print] doi:10.1007/s10689-012-9521-y.